Nivolumab 3 mg/kg every 2 weeks (Q2W) has been approved in Japan for various cancers; however, use of a flat dose is expected to simplify dosing and administration.
| INTRODUC TI ON
Nivolumab is a fully human IgG4 monoclonal antibody that binds programmed death 1 (PD-1) on activated T cells to act as an antagonist and potentiate T-cell responses. 1 The first global approval for nivolumab was in Japan in 2014 for the treatment of unresectable melanoma. 2 Nivolumab is now approved for first-line treatment of patients with unresectable or metastatic melanoma (as monotherapy or in combination with ipilimumab) and as a second-line agent for patients with metastatic non-small cell lung cancer (NSCLC), advanced renal cell carcinoma (RCC), classical Hodgkin lymphoma (cHL), squamous cell carcinoma of the head and neck (SCCHN), and urothelial cancer (UC) in the United States and the European Union, as well as for metastatic colorectal cancer and hepatocellular carcinoma in the United States. 3 In addition, nivolumab was recently approved as an adjuvant treatment for patients with completely resected melanoma in the United States. 3 Nivolumab was initially approved at a weight-based dose of 2 mg/kg every 3 weeks in Japan 2 and 3 mg/kg every 2 weeks (Q2W) in the United States and the European Union. 4 Use of nivolumab at 3 mg/kg Q2W in Japan was approved after its efficacy and safety were demonstrated in Japanese patients. 5 Evaluation of pharmacokinetics in patients with solid tumors has shown that 1, 3 and 10 mg/ kg doses of nivolumab result in somewhat higher exposure (reflected by maximum plasma concentration and area under the concentration-time curve) in Japanese and Korean patients versus those from the United States but that these small differences would not be expected to have an impact on efficacy or safety. 6 Investigations into exposure levels for monoclonal antibody therapy found that most of these antibody treatments demonstrate relatively flat dose-response relationships, [7] [8] [9] [10] suggesting that a body-weight-based regimen may not be necessary. It has also been shown that body-weight-based dosing does not always offer an advantage over flat dosing for decreasing exposure variability and that the pharmacokinetic variability from either a flat-dose or a bodyweight regimen is moderate when considering resulting pharmacodynamics, efficacy and safety. 11 Specifically, an exposure-response (E-R) analysis of nivolumab in previously untreated patients with advanced melanoma reported that the time-averaged concentration after the first dose of nivolumab is not a significant predictor of overall survival (OS) in patients with advanced melanoma treated with doses ranging between 0.1 and 10 mg/kg every 2 weeks. 12 Similar results have been reported from E-R analyses of data from patients with NSCLC, where no significant association between nivolumab exposure and OS or toxicity was found. 10 A potential benefit of flat dosing is simplified administration of a drug across a wide range of tumor types, providing greater convenience to healthcare providers by helping to facilitate dosing calculations and drug preparation, improving patient compliance, and possibly helping to reduce healthcare costs. 4, 9, 13, 14 In addition, preparation of a body-weight dose may result in excess drugs being prepared, which could be avoided with a flat dose. Lack of excess drug will help reduce both the waste of product and the potential for inappropriate use of prepared medicine between patients. 14 For example, improper use of a single prepared medication vial has been associated with infection events and outbreaks in the outpatient setting. 16 Of 26 infection outbreaks that occurred due to unsafe injection practices in healthcare facilities, 73% were associated with sharing a single prepared vial with more than one patient. 15 Given that nivolumab has linear PK over a dose range of 0.1 to 10 mg/kg across multiple tumor types, the 240 mg Q2W regimen has been proposed based on the approximate median body weight of 80 kg for subjects treated in nivolumab clinical trials (N = 3458). 4 Most phase 3 clinical trials for multiple tumor types are currently conducted with 240 mg flat dose. ICH E17 states that the dose regimens in confirmatory multi-regional clinical trials should in principle be the same in all participating ethnic population unless earlier trial data show a clear difference in dose-response and/or exposure-response relationships for an ethnic population. 17 Based on a demonstration of the similarity of predicted exposure and efficacy/safety responses in population pharmacokinetic (PPK) and E-R analyses, 4, 13 a 240 mg flat dose is selected and investigated for a Japanese population as well as a non-Japanese population in accordance with ICH
E17.
Data from both global and regional Japanese studies were used to conduct the E-R analyses presented here to characterize the relationship between nivolumab exposure and its efficacy and safety in the Japanese population and to assess the potential impact of changing from a 3 mg/kg Q2W dose to a 240 mg Q2W dose. Efficacy outputs were generated for patients diagnosed with advanced melanoma, squamous (SQ) or non-squamous (NSQ) NSCLC, or RCC, and safety outputs were generated for the total Japanese population across a range of tumor types. Specifically, safety, OS, and objective response rate (ORR) of nivolumab at the flat dose of 240 mg Q2W were compared to those of the 3 mg/kg Q2W body-weight-normalized dose in global and Japanese patient populations.
| MATERIAL S AND ME THODS

| Patient population
Data from 10 global studies and 5 regional studies (ONO-4538-01, ONO-4538-02, ONO-4538-05, ONO-4538-06 and ONO-4538-08) of Japanese patients with various cancers (eg, melanoma, NSCLC, RCC, colorectal cancer, cHL, UC and SCCHN) were used in the safety and efficacy analyses described here. Doses for the analyses ranged from 1 to 10 mg/kg. Study descriptions and study numbers, number of Japanese patients and analysis type are all displayed in Table S1. which has been shown to be associated with an efficacy response. 18 Cavgd28 was log-transformed because it spanned more than a 10fold range.
| Pharmacokinetic model
| Exposure-response analysis of safety
Three safety endpoints were selected to investigate a broad spectrum of clinically relevant adverse events (AE) and any potential differences between the two doses in global and Japanese studies (Table S1): AE that led to discontinuation (excluding those due to disease progression) or death (AE-DC/D); grade 3 or higher AE (AE-Grade 3+); and grade 2 or higher immune-mediated AE (AE-IM Grade 2+). A logistic regression model was developed using data from 2560 global patients, which was updated to include data from 273 Japanese patients to predict safety outcomes. In this model, the probability that patient i will experience an AE is given by:
where X i represents the predictor variables and β o and β are the estimated parameters of the model.
| Exposure-response analysis of efficacy
Both OS and ORR were used as efficacy endpoints to assess and compare predicted efficacy of nivolumab 240 mg Q2W and 3 mg/kg Q2W in the noted global and Japanese studies (Table S1 ). Separate models for OS and ORR were developed from studies of patients diagnosed with melanoma, NSCLC (SQ and NSQ) or RCC. E-R models of OS and ORR that included 1749 and 1710 patients, respectively, now included 134 Japanese patients from regional studies. Individual survival probabilities for each patient were averaged to obtain a predicted OS curve, and mean survival probabilities at 1 and 2 years for each dose were also predicted. The predicted response rates for each dose were compared with that of control arms (ie, standard of care).
Relationships between nivolumab exposure and OS and ORR, ad-
After model qualification by a visual predictive check, the models were used to predict hazard and odds ratios (200 and 1000 times, respectively, for OS and ORR) for each dose regimen. The median values and 95% confidence intervals (CI) were summarized and compared.
| Safety and efficacy predictor
Various predictor variables (ie, body weight, age, sex, performance score, line of therapy and tumor type baseline clearance), in addition to nivolumab exposure, were assessed to estimate whether each would have an impact on the safety or efficacy of nivolumab treatment. An increased or decreased risk was determined based on hazard ratios. If a 95% CI range included 1.0, then the associated variable was not considered a significant prognostic factor for safety or efficacy. For example, a hazard ratio <1.0 for body weight and a CI range that does not include 1.0 would suggest a significantly increased risk for patients with a lower body weight. The variables assessed included log-transformed Cavgd28, multiple baseline characteristics, prior treatment and tumor type (safety only). Ethnicity (Japanese vs non-Japanese) was evaluated as a covariate for melanoma and NSCLC (SQ and NSQ) in the efficacy analysis.
| RE SULTS
| Comparisons of nivolumab exposure
The geometric mean and median of nivolumab exposure for E-R safety analyses (Table 1) were computed for 273 Japanese patients enrolled in 9 different studies (Table S1) Figure S1 ). Overall, exposure was higher for the 240 mg Q2W dose compared with the 3 mg/kg Q2W dose; specifically, the geometric mean Cavgd28 was 37% higher. When exposure was assessed in the E-R efficacy analysis across tumors in 134 Japanese patients,
a similar trend of a 28% to 35% increase in mean exposure was observed for the flat dose relative to the body-weight dose (Table S2 ). including Japanese patients (Table S3 ). The odds ratios for nivolumab Cavgd28 to cause either an AE-DC/D or AE-Grade 3+ were 1.23 and 0.91, respectively. The 95% CI for these ratios included 1, indicating that increasing the nivolumab dose did not significantly impact the occurrence of AE-DC/D or AE-Grade 3+ in the tumor types assessed here. A slightly higher risk for AE-IM Grade 2+ in patients with a higher nivolumab exposure (odds ratio 1.01; 95% CI 1.00, 1.01) was predicted, which may be due to the interaction of nivolumab with the immune system (discussed further below). Lower body weight was mildly associated with an elevated risk of developing an AE-DC/D (odds ratio 0.98; 95% CI 0.97, 0.98). Having a performance score >0, more than one line of previous therapy and an increased clearance level were all identified as factors associated with a significantly increased chance of developing an AE-DC/D or an AE-Grade 3+.
|
| Exposure-response analysis of efficacy
Prediction of mean 1-year and 2-year OS probabilities based on the 240 mg Q2W or 3 mg/kg Q2W dosages is presented in Table 2 .
The mean OS for the proposed 240 mg Q2W regimen and the ap- Table S4 . Hazard ratios and 95% CI suggest a significantly increased risk of death for both lower body weight and higher baseline clearance level across all four tumor types assessed.
Elevated LDH in patients with melanoma or NSCLC (SQ and NSQ) and a higher Cavgd28 in patients with melanoma were each predicted to significantly increase risk of death. In patients with NSQ-NSCLC, a decreased risk of death was identified for Japanese versus non-Japanese patients.
Baseline and other variables were also assessed for relation to ORR for melanoma, RCC or NSCLC (SQ and NSQ) and are shown in There was no significant association (the 95% CI for the odds ratio included 1) between Cavgd28 of nivolumab and AE-DC/D or AE-Grade 3+. Body weight was significantly associated with AE-DC/D (odds ratio 0.98 [95% CI 0.97, 0.98]). It should be noted, however, that body weight was not a significant predictor of AE-IM Grade 2+, and the E-R was also relatively flat for this measure of safety. AE-IM is considered to be a more relevant measure of safety to assess the impact of a change in nivolumab dose than AE-DC/D, as AE-IM is more likely to be related to the mechanism of action of nivolumab. 21, 22 Overall, the predicted safety profiles of nivolumab at 240 mg Q2W and 3 mg/kg Q2W were comparable, and the impact of flat dosing on AE risk was minimal.
| D ISCUSS I ON
In patients with melanoma, the risk of death seemed to be slightly higher with higher Cavgd28; however, there was overlap with regard to 95% CI in the predicted mean OS. The predicted mean 1-year and 2-year OS were quite similar for the flat and weight-based doses, suggesting that a flat dose is unlikely to result in any clinically meaningful differences in efficacy. The increased risk of death for higher clearance, higher baseline LDH, and lower body weight in patients with melanoma 23 or NSCLC 10 observed in this analysis has been reported previously.
Results from the variable estimate analysis suggested that there may be a lower risk of death in Japanese versus non-Japanese patients for those diagnosed with NSQ-NSCLC (95% CI 0.42, 0.99). It is worth noting that the percentage of patients who received subsequent therapy out of those who experienced disease progression or death is higher in the Japanese study (ONO-4538-06/CA209-132; 83.6%) than in the global study (CA209-057; 58.3%).
Unlike for melanoma and NSCLC, there was no regional Japanese study for patients with RCC; therefore, the model to predict ORR for RCC was not updated. The global phase 3 study (CA209-025) for RCC, however, did enroll 37 Japanese patients, who were included in the datasets from the previous analyses.
For this global RCC study, the predicted median nivolumab ex- 
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